Download PDF
Thromb Haemost 2004; 92(06): 1232-1239
DOI: 10.1160/TH04-04-0216
Theme Issue Article
Schattauer GmbH

The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury

Chieh-Yu Peng   *
1   Pharmacological Institute
,
Shiow-Lin Pan   *
1   Pharmacological Institute
,
Jih-Hwa Guh
2   School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
,
Yi-Nan Liu
1   Pharmacological Institute
,
Ya-Ling Chang
1   Pharmacological Institute
,
Sheng-Chu Kuo
3   Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung, Taiwan
,
Fang-Yu Lee
4   Yung-Shin Pharmaceutical Industry Co, Ltd, Taichung, Taiwan
,
Che-Ming Teng
1   Pharmacological Institute
› Author Affiliations
Further Information

Publication History

Received 05 April 2004

Accepted after resubmission 10 September 2004

Publication Date:
02 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Proliferation of vascular smooth muscle cells (VSMCs) is postulated to be one of the key events in the pathogenesis of atherosclerosis and restenosis. We investigated whether YD-3, a lowmolecular weight, non-peptide compound, could modulate proliferation of VSMCs in vitro and restenosis after balloon angioplasty in vivo. We examined the effect of YD-3 on thrombininduced VSMC proliferation by [3H]thymidine incorporation assay. The data demonstrated that YD-3 inhibited VSMC proliferation in a concentration-dependent manner. To define the mechanisms of YD-3 action, we found that YD-3 showed a profound inhibition on thrombin-induced Ras and ERK1/2 activities by using Western blotting analysis. Furthermore, oral administration of YD-3 exhibited a marked reduction in neointimal thickness using the carotid injury model in rats. Using immunochemical detection, our experiments also revealed that YD-3 significantly suppressed expression of the PAR-1 receptor, and markedly inhibited PAR-1-activating peptide (SFLLRN)-induced VSMC proliferation in a concentration-dependent manner. These results suggest that YD-3 inhibits thrombin-induced VSMC growth via the Rasand ERK1/2-mediated signaling pathway. Moreover, YD-3 also shows a developmental potential in the treatment of atherosclerosis and restenosis after vascular injury.

Keywords

YD-3 - vascular smooth muscle cells - thrombin - restenosis - signal transduction

* Chieh-Yu Peng and Shiow-Lin Pan contributed equally to this work


 

  • References

  • 1 Eidt JF, Allison P, Noble S. et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27.
    CrossrefPubMedGoogle Scholar
  • 2 McNamara CA, Sarembock IJ, Gimple LW. et al. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-8.
    CrossrefPubMedGoogle Scholar
  • 3 Vu TK, Hung DT, Wheaton VI. et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
    CrossrefPubMedGoogle Scholar
  • 4 Ishihara H, Connolly AJ, Zeng D. et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
    CrossrefPubMedGoogle Scholar
  • 5 Kahn ML, Zheng YW, Huang W. et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
    CrossrefPubMedGoogle Scholar
  • 6 Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-7.
    CrossrefPubMedGoogle Scholar
  • 7 Fuster V, Badimon L, Badimon JJ. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-50.
    CrossrefPubMedGoogle Scholar
  • 8 Libby P, Schwartz D, Brogi E. et al. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86: 11147-52.
    PubMedGoogle Scholar
  • 9 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
    CrossrefPubMedGoogle Scholar
  • 10 Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994; 81: 1254-69.
    CrossrefPubMedGoogle Scholar
  • 11 Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis 1997; 40: 107-16.
    CrossrefPubMedGoogle Scholar
  • 12 Takada M, Tanaka H, Yamada T. et al. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res 1998; 82: 980-7.
    CrossrefPubMedGoogle Scholar
  • 13 Wilcox JN, Rodriguez J, Subramanian R. et al. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75: 1029-38.
    CrossrefPubMedGoogle Scholar
  • 14 Nelken NA, Soifer SJ, O’Keefe J. et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-21.
    CrossrefPubMedGoogle Scholar
  • 15 Wu CC, Huang SW, Hwang TL. et al. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol 2000; 130: 1289-96.
    CrossrefPubMedGoogle Scholar
  • 16 Wu CC, Hwang TL, Liao CH. et al. Selective inhibition of protease-activated receptor 4dependent platelet activation by YD-3. Thromb Haemost 2002; 87: 1026-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Wu CC, Hwang TL, Liao CH. et al. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost 2003; 90: 299-308.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Cheung WM, D’Andrea MR, AndradeGordon P. et al. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol 1999; 19: 3014-24.
    CrossrefPubMedGoogle Scholar
  • 19 Pan SL, Guh JH, Huang YW. et al. Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. J Biomed Sci 2002; 09: 622-30.
    CrossrefPubMedGoogle Scholar
  • 20 Cobb MH, Hepler JE, Cheng M. et al. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 1994; 05: 261-8.
    PubMedGoogle Scholar
  • 21 Lowes VL, Ip NY, Wong YH. Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals 2002; 11: 5-19.
    CrossrefPubMedGoogle Scholar
  • 22 Lin CC, Shyr MH, Chien CS. et al. Thrombinstimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells. Cell Signal 2002; 14: 265-75.
    CrossrefPubMedGoogle Scholar
  • 23 Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-33.
    PubMedGoogle Scholar
  • 24 Rivard A, Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol Histopathol 2000; 15: 557-71.
    PubMedGoogle Scholar
  • 25 Walz DA, Anderson GF, Ciaglowski RE. et al. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med 1985; 180: 518-26.
    CrossrefPubMedGoogle Scholar
  • 26 Hatton MW, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499-508.
    PubMedGoogle Scholar
  • 27 Freedman JE. Thrombin, thrombomodulin, and extracellular signal-regulated kinases regulating cellular proliferation. Circ Res 2001; 88: 651-3.
    CrossrefPubMedGoogle Scholar
  • 28 Schieffer B, Drexler H, Ling BN. et al. G protein-coupled receptors control vascular smooth muscle cell proliferation via pp60csrc and p21ras. Am J Physiol 1997; 272: C2019-30.
    CrossrefPubMedGoogle Scholar
  • 29 Jones SM, Kazlauskas A. Growth factordependent signaling and cell cycle progression. FEBS Lett 2001; 490: 110-6.
    CrossrefPubMedGoogle Scholar
  • 30 Luttrell LM. Activation and targeting of mitogen-activated protein kinases by G-proteincoupled receptors. Can J Physiol Pharmacol 2002; 80: 375-82.
    CrossrefPubMedGoogle Scholar
  • 31 Campbell SL, Khosravi-Far R, Rossman KL. et al. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-413.
    CrossrefPubMedGoogle Scholar
  • 32 Ayllon V, Rebollo A. Ras-induced cellular events (review). Mol Membr Biol 2000; 17: 65-73.
    CrossrefPubMedGoogle Scholar
  • 33 Wagner AC, Williams JA. Low molecular weight GTP-binding proteins: molecular switches regulating diverse cellular functions. Am J Physiol 1994; 266: G1-14.
    CrossrefPubMedGoogle Scholar
  • 34 Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci U S A 1975; 72: 131-5.
    CrossrefPubMedGoogle Scholar
  • 35 Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56: 139-45.
    CrossrefPubMedGoogle Scholar
  • 36 Macfarlane SR, Seatter MJ, Kanke T. et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-82.
    PubMedGoogle Scholar